Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SXRN in Advanced Solid Tumors and Cachexia
NCT06736275Phase 1Recruiting
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SXRN in solid tumor and cachexia (3 arms), sponsored by Jiangsu Nutai Biologics Co., Ltd. Primary endpoints: Maximum Tolerated Dose and Recommended Dose for Expansion at 12 months, Effect for SXRN on Appetite compared to placebo and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
SXRN
03
Conditions
solid tumorcachexia
Beyond the preview
Go deeper on NCT06736275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736275.